Loading...
•
Sep 30, 2021
Agenus Q3 2021 Earnings Report
Agenus reported financial results for the third quarter of 2021 and provided a corporate update.
Key Takeaways
Agenus reported a net income of $177 million, or $0.76 per share basic and $0.72 per share diluted, and ended the quarter with $262 million in cash and short-term investments. The company also highlighted clinical responses achieved with AGEN1181, the launch of MiNK Therapeutics' IPO, and the launch of its adjuvant business, SaponiQx.
AGEN1181 shows clinical benefit in 9 cold and treatment-resistant tumor types.
MiNK Therapeutics launched an IPO and is trading on NASDAQ.
SaponiQx launch to accelerate development of proven and novel adjuvants.
First patients dosed in multiple collaborator programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...